You are here

  • Home
  • Archive
  • Volume 98, Issue 4
  • High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype
  1. Young-Hoon Jeong1,2,
  2. Yongwhi Park2,
  3. Kevin P Bliden1,
  4. Udaya S Tantry1,
  5. Paul A Gurbel1
  1. 1Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
  2. 2Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
  1. Correspondence to Professor Paul A Gurbel, Cardiac Catheterization Laboratory, Sinai Center for Thrombosis Research, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA; pgurbel{at}lifebridgehealth.org

https://doi.org/10.1136/heartjnl-2011-301129

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor The study performed by Breet et al1 supported our previous suggestion that a cut-off of >550 aspirin reaction units (ARU) was too high to identify high on-treatment platelet reactivity (HPR).2 The cut-off defined by the highest quartile (461 ARU) from our study2 is remarkably similar to the 454 ARU cut-off value associated with 1-year outcomes in the Breet et al study.1 Moreover, across ARU quartiles, reactivity to ADP and collagen …

    View Full Text

    Footnotes

    • Funding This study was partly supported by grants from the Institute of the Health Sciences, Gyeongsang National University and Sinai Hospital Baltimore.

    • Competing interests Dr Jeong received honoraria from Sanofi-Aventis, Daiichi Sankyo Inc. and Otsuka. Dr Gurbel received research grants, honoraria and consultant fees from Haemoscope, AstraZeneca, Schering-Plough/Merck, Medtronic, Lilly/Daiichi Sankyo Inc., Sanofi-Aventis/Bristol Myers, Portola, Boston Scientific, Bayer, Novartis, Accumetrics, Boehringer Ingelheim and Johnson & Johnson.

    • Patient consent Obtained.

    • Ethics approval Ethics approval was obtained from the Gyeongsang National University Hospital institutional review board.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • PostScript
      The Authors' reply
      Nicoline J Breet Jochem W van Werkum Heleen J Bouman Johannes C Kelder Ankie M Harmsze Christian M Hackeng Jurriën M ten Berg
      Heart 2012; 98 343-344 Published Online First: 20 Jan 2012. doi: 10.1136/heartjnl-2011-301435